Literature DB >> 19907421

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

A L Zackrisson1, B Lindblom, J Ahlner.   

Abstract

In Sweden, about 550 individuals die every year of drug intoxication. Many of these drugs are metabolized by CYP enzymes such as CYP2D6 and CYP2C19. A lack of these enzymes, resulting in poor metabolism, can lead to adverse reactions and even to fatality. On the other hand, an ultrarapid metabolism can lead to insufficient drug plasma concentration, resulting in failure of treatment, or it can lead to high concentrations of active/toxic metabolites. The aim of this project was to study the genetic profile of individuals with regard to the presence of CYP2D6 and CYP2C19 genes, in cases of fatal intoxication (242), suicide (intoxications excluded) (262), and natural death (212). PCR, followed by pyrosequencing, was used for all the analyses. We found that, among those who died of suicide (suicide cases), there was a higher number carrying more than two active CYP2D6 genes (corresponding to the phenotype of ultrarapid metabolizer) as compared with those who died of natural causes (natural-death cases) (P = 0.007).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19907421     DOI: 10.1038/clpt.2009.216

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  35 in total

1.  The promises of personalized medicine.

Authors:  Ingolf Cascorbi
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953

Review 2.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 3.  Pharmacogenomics of suicidal events.

Authors:  David Brent; Nadine Melhem; Gustavo Turecki
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

Review 4.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

5.  Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

Authors:  H Andresen; C Augustin; T Streichert
Journal:  Int J Legal Med       Date:  2012-08-17       Impact factor: 2.686

Review 6.  Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.

Authors:  Chiara Fabbri; Alessandro Serretti
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

7.  Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol.

Authors:  Jie Li; Mengmeng Xie; Xiaoshuang Wang; Xiufang Ouyang; Yu Wan; Guicheng Dong; Zheqiong Yang; Jing Yang; Jiang Yue
Journal:  Br J Pharmacol       Date:  2015-08-26       Impact factor: 8.739

Review 8.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

9.  Impact of cytochrome P450 genes on suicide attempt and risk.

Authors:  Eva M Peñas-Lledó; M Eugenia G Naranjo; Adrián Llerena
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-16       Impact factor: 5.270

Review 10.  Challenges in pharmacogenetics.

Authors:  Ingolf Cascorbi; Oliver Bruhn; Anneke N Werk
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.